Connect with us

Stroke news

Aidoc: The international one-stop shop AI solution



Aidoc provides a comprehensive AI-powered stroke triage and notification solution to hospitals around the world. The software has been designed to speed up treatment of both ischemic and haemorrhagic stroke.

Alexander Boehmcker is Aidoc’s European Vice President. We chatted with the former Aidoc customer to find out how the Israeli company is staying ahead of the game in a highly competitive marketplace.

What is Aidoc’s stroke triage and notification solution?

The stroke solution consists of an application for the flagging of intracranial haemorrhage, large vessel occlusion (LVO) and CT perfusion.

We partnered with Icometrix, adding another solution to our existing slate of neuroscience-geared algorithms, which enhances a physician’s ability to identify ischemic stroke.

The solution includes a communication element, which enables different specialties to communicate with each other via mobile chat. This can be used both in an individual hospital setting, as well as across the different hospitals.

How does Aidoc differ from other AI stroke solutions?

Firstly, I believe that Aidoc differentiates itself by the breadth of the portfolio.

I think we’re the leading company in terms of having 10 CE Mark solutions. And that is important for a hospital that is looking to integrate solutions for numerous pathologies and only have to deal with one vendor, which means the integration process is simpler.

Secondly, it has a very large footprint, implemented in over 900 healthcare systems worldwide. We are commercial in 11 European countries and implemented Brazil and Australia.

The United States is a very important market for us as well. I believe that having a significant presence in the US is essential to the future of any AI company.

Also, we are coming from Israel, so we have very close links to the country’s innovative healthcare system.

Alexander Boehmcker

How has Aidoc integrated itself within international healthcare systems?

Aidoc has an outstanding customer success team, which is assuring that individual solutions are implemented and validated in a very local environment.

Firstly, you need to bring a validated, accurate AI solution through the certification process to get your CE marking. Then you have to demonstrate that your solution works and provides value in a very specific local environment.

We have published 29 peer-reviewed clinical studies, providing evidence of accuracy, quality assurance, efficiency and flagging of acute patients.

You also have quite a significant footprint in the NHS…

We are probably in two-thirds of all NHS hospitals, mainly by via teleradiology providers.

Teleradiology providers are very early adopters of the technology. They serve a large footprint of the NHS hospital trusts, so many patients are already benefitting from AI solutions. Not during the whole day, sometimes just during the night.

But we’re now working towards servicing NHS hospitals during daytime.

We don’t believe that there should be a different standard of care for patients who come into nighttime emergency after being reported by teleradiology compared to on-site, daytime patients.

Have you noticed a shift in demand for your technologies during the pandemic?

In recent years, we have seen an increasing gap between supply and demand of radiologist capacity.

You see an ever-increasing amount of cases coming through due to ageing population and more diagnostics early in the treatment chain, combined with a scarcity of radiologists.

The last Royal College of Radiologists workforce census identified a gap of 2000 radiologists just for the UK.

It takes 10 years to train a radiologist. I believe that the only way how to close that gap between supply and demand is via technology.

The pattern of demand has changed during the pandemic. We have seen a delay in many of the planned procedures.

Meanwhile, emergency has continued to be more or less on the same level. A few car accidents that did not happen were offset by people being injured in accidents at home.

So as a provider of emergency care, we’ve been very busy.

What about the impact of Covid itself?

A significant body of evidence shows increased prevalence of both stroke and pulmonary embolism due to Covid.

What was already high workload has been even increasing more. This is really stretching NHS capacity, with average A&E waiting times on the increase.

We’ve been seeing is a 37 per cent increase to now nearly five and a half hours average waiting time. This means we should embrace technology, which enables us and supports us in triaging these highly critical, sick patients and prevent a ticking time bomb.

What are your plans for the rest of 2022 and beyond in term of stroke and in your other indications?

We have several development angles. Aidoc has a very strong background of developing individual AI algorithms modules which target towards individual pathologies, like intracranial haemorrhage and LVOs.

What we’re now doing more and more is combining these algorithms to so-called Care Coordination Solutions, where stroke is very good example.

Another already in place is specifically for pulmonary embolisms. And there are a further 10 identified use cases which will follow suit.

We also want to further develop our AI platform. We will continue to integrate third party solutions to grow our offering for existing customers and attract new customers so we can truly become a one-stop shop.

Specifically for stroke, we are looking to support the detection of even more detailed occlusions, not only LVOs. These technologies will go into the more distal areas, offering a lot of flexibility.